Matt Papa

Matthew brings nearly 15 years of diverse leadership experience across the pharmaceutical industry, with a proven track record in corporate strategy, M&A, licensing and product lifecycle management. In 2025, he joined Currax from Sun Pharma, where he served as Senior Director of Corporate Strategy and Business Development for North America. In that role, he made meaningful contributions to expand Sun’s specialty portfolio through multiple high impact transactions, including the $355 million acquisition of Checkpoint Therapeutics, the $576 million acquisition of Concert Pharmaceuticals and the global licensing agreement for Fibromun, a novel oncology asset.

Prior to Sun, Matthew spent six years at Salix Pharmaceuticals, where he held multiple leadership roles, including Director of Corporate Strategy and Business Development, Regional Sales Manager, and Senior Product Manager for Xifaxan.

Earlier in his career Matthew held roles of increasing responsibility at Bristol-Myers Squibb across regulatory strategy, medical affairs and sales. Matthew earned his Doctorate of Pharmacy and Bachelor of Science in Pharmacy Studies from the University of Connecticut and holds an MBA from Duke University’s Fuqua School of Business.